Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGNRZU)

• Drug Name: PMID27376512-Compound-MTC-424 Drug Info
• Cross-matching ID: TTD Drug ID: DMGNRZU

Molecule-Related Drug Atlas

Drug(s) Targeting DNA [cytosine-5]-methyltransferase 3A (DNMT3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27376512-Compound-MTC-427	DMWXEZD	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-MTC-422	DM1MVQD	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-MTC-423	DM9RSDX	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-Figure2aExample1	DMP59OX	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-Figure3CN	DMP7DL6	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-Figure3CG	DMZIKN6	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-Figure3CM	DMIS4H0	N. A.	N. A.	Patented	[1]

Drug(s) Targeting DNA [cytosine-5]-methyltransferase 3B (DNMT3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]
PMID27376512-Compound-MTC-427	DMWXEZD	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-MTC-422	DM1MVQD	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-MTC-423	DM9RSDX	N. A.	N. A.	Patented	[1]
(L-)-S-adenosyl-L-homocysteine	DMDUN83	Discovery agent	N.A.	Investigative	[3]
NSC-622445	DME35CB	Discovery agent	N.A.	Investigative	[2]
NSC-622444	DMM5UT9	Discovery agent	N.A.	Investigative	[2]
NSC-138419	DMH684Q	Discovery agent	N.A.	Investigative	[2]
NSC-319745	DMF3G06	Discovery agent	N.A.	Investigative	[2]
NSC-348926	DM3TDEO	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting DNA [cytosine-5]-methyltransferase 1 (DNMT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CC-486	DMTNQB0	Acute myeloid leukaemia	2A60	Phase 3	[4]
S-110	DMXY34J	Acute myeloid leukaemia	2A60	Phase 3	[5]
SGI110	DM1NQDW	Acute myeloid leukaemia	2A60	Phase 3	[6]
Guadecitabine	DM9Y3EG	Myelodysplastic syndrome	2A37	Phase 3	[7]
Palifosfamide	DMMIYZ7	Soft tissue sarcoma	2B57	Phase 2	[8]
RX-3117	DME8ARP	Bladder cancer	2C94	Phase 2	[9]
Antroquinonol	DMRGQVZ	Non-small-cell lung cancer	2C25.Y	Phase 2	[10]
GSK4172239	DM930LE	Sickle-cell disorder	3A51	Phase 1	[11]
PMID27376512-Compound-MTC-427	DMWXEZD	N. A.	N. A.	Patented	[1]
PMID27376512-Compound-MTC-422	DM1MVQD	N. A.	N. A.	Patented	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA [cytosine-5]-methyltransferase 1 (DNMT1)	TT6S2FE	DNMT1_HUMAN	Inhibitor	[1]
DNA [cytosine-5]-methyltransferase 3A (DNMT3A)	TTJUALD	DNM3A_HUMAN	Inhibitor	[1]
DNA [cytosine-5]-methyltransferase 3B (DNMT3B)	TT6VZ78	DNM3B_HUMAN	Inhibitor	[1]

References

• [1] DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
• [2] Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
• [3] Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
• [4] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
• [5] S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
• [6] Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
• [9] Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
• [10] Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline